Daily Equity Reports 08 Feb 2019

1. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647 DAILY EQUITY REPORT 08 THFEBRUARY 2019 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

2. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report INDIANFACE INDIAN MARKET CLOSE PREVIOUS ! INDIANEQUITYBENCHMARK- Benchmarkindicesended flatonThursdaywithNiftyendedabove11,000level.RBIin itsMPCmeetinghascutreporateby25bpsat6.25percent. NIFTY TheSensexwasdown4.14pointsat36971.09,whileNifty CLOSE PREVIOUS was up 6.90 pointsat 11069.40.About1377 shares have advanced, 1145 shares declined, and 164 shares are NIKKEI unchanged. 2203.42 2203.46 SECTORIAL INDICES GLOBALFACE INDICES CLOSE CHANGE (%) ! 0.21 CNX 100 AsianMarket- Asianmarketsfinishedmixedasofthemost recent closingprices.TheShanghaiCompositegained1.30% 9145.80 0.30 S&P CNX 500 andtheHangSengrose0.21%.TheNikkei225lost0.59%. 4658.25 0.77 ! 5770.15 0.27 U.S.Market– NorthandSouthAmericanmarketsfinished broadly loweronWednesdaywithsharesinBrazilleading CNX 200 BANK NIFTY theregion.TheBovespaisdown3.74%whileMexico'sIPCis off1.09%andU.S.'sS&P500 islowerby0.22%. TOP GAINERS CLOSE CHANGE (%) ! 4.56 Europeanmarkets- Europeanmarketsaremixed.TheFTSE 100ishigherby0.02%,whiletheDAXisleadingtheCAC40 lower.Theyaredown0.59%and0.34%respectively. SUNPHARMA 4.13 3.56 BAJAJ-AUTO 2,853.65 3.01 TOP LOSERS CLOSE CHANGE (%) -2.35 RELIANCE 1,288.00 -1.70 1,295.15 -1.46 -1.18 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

3. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report NIFTYSPOT MARKET MOVERS UPSIDE TREND BULLISH STRATEGY BUY ON DIPS SCRIPT CLOSE (%) 4.56 ZEEL PIVOT POINTS 2.86 S3 10922 S2 10997 R1 11100 R2 11146 R3 11220 11025 11071 2.82 INFRATEL S1-11025 S2-10997 R1-11100 R2-11146 2.63 CLOSE (%) -2.35 JSWSTEEL -1.13 HDFC NTPC -0.88 -0.71 NET BUY (CR.) NET SELL (CR) 4040.48 STRATEGY BUY ON DIPS BULLISH DII 3509.34 PIVOT POINTS P 27454 S1 27261 R1 27608 R2 R3 28148 NSE TOTALS ADVANCE 26760 27107 27801 RESISTANCE S BANK NIFTY NIFTY BANK NIFTY 6 Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

4. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report MARKET TALKS SunPharmastockgains4.5%after! subsidiaryTaropostsstrongnumbers SharesofSunPharmagained4.5%ontheNSEinmorning tradeafteritsUSsubsidiaryTaroPharmareportedstrong quarterlyresults.TaroPharmaceuticalspostednetsalesof $176.4mn,anincreaseof$20.9mn,mainlydrivenbya 13%increaseinoverallvolumes.Itsgrossprofitof$117.5 mn (66.6% of net sales compared to 66.2%) increased $14.6mn.NetincomeattributabletoTarowas$93.5mn compared to $18mn, a $75.5mn increase, resulting in diluted earnings per share of $2.40 compared to $0.45. Excludingtheimpactoftheaforementionedone-timetax re-measurement in the prior year quarter, net income attributabletoTarowouldhavebeen$54.8mn,ordiluted earningspershareof$1.37. ! Ciplagetsfinalapprovalforgeneric versionofTadalafiltablets CiplahasreceivedfinalapprovalforitsAbbreviatedNew Drug Application (ANDA) for Tadalafil Tablets 20mg from the USFDA. Ciplas Tadalafil Tablets 20mg is AB- ratedgenerictherapeuticequivalentversionofEliLilly & Co.s Adcirca. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterialhypertension(PAH)(WHOGroup1)toimprove exerciseability.AccordingtoIQVIA(IMSHealth),Adcirca and its generic equivalents approximately$490mnforthe12-monthperiodending November 2018. The productis available for shipping immediately. had US sales of ! GlenmarkgetstentativeANDAnodfor Fulvestrantinjection GlenmarkgetstentativeANDAnodforFulvestrant injectionGlenmarkscurrentportfolioconsistsof148 productsauthorizedfordistributionintheUSmarketplace and54ANDAspendingapprovalwiththeUSFDA. GlenmarkPharmaceuticalsGlenmarkPharmaceuticals Inc.,USA(Glenmark)hasbeengrantedtentativeapproval bytheUnitedStatesFood&DrugAdministration(USFDA) forFulvestrantInjection,250mg/5ml(50mg/ml),a genericversionofFASLODEXInjection,250mg/5ml(50 mg/ml),ofAstraZenecaPharmaceuticalsLP. ! GAILtakesbackgaspipelinelayingcontractfrom IL&FS GAIL(India)initspressnotetotheexchangesinformedthat,as the ownerandoperatorofthePradhanMantriUrjaGanga naturalgaspipelineprojectunderexecution,ithasoffloadedthe pipelayingcontractfromIL&FSduetopoorprojectprogress drivenonaccountoftheacutefinancialcrisis. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

5. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. Daily Equity Report NAME OF THE STOCK : HINDUNILVR DATE : 08/02/2019 SEGMENT : CASH CHART TYPE : Candlestick EXCHANGE : NSE TECHNICAL INDICATORS USED : VOLUME.MACD,RSI. CHART INVESTMENTADVICE: CALLCS CALL:- BUY HINDUNILVR IN CASH NR CMP 1840 TGT 1880 SL 1800 RATIONALEFORARRIVINGINVESTMENTADVICE: TECHNICALVIEW: THE STOCK TECHINCALLY IS UP ,TAKING SUPPORT OF VOLUME.RESISTANCE IS BROKEN TODAY WITH HEAVY VOLUME.AS WELL AS A POSSIBILITY OF TREND REVERSAL IS THERE. OTHER REASON IF ANY :- SHOWING STRENGTHS IN INTRADAY CHARTS AS WELL. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

6. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. DISCLAIMER The information and views in this report & all the service we provide are believed to be reliable, but we do not accept any responsibility for errors of fact or opinion. Investors have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility. The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. My research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Capitalstars shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of regulators. The price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for. Investment & Trading in Securities Markets are always subjected to market risk. Capitalstars Financial Research Private Ltd., Reserves all Rights. INVESTMENT AND TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISK. Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

7. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. CapitalStars Financial Research Private Limited is an advisory company incepted with a vision of providing fair and accurate trading and investment calls in share and commodity market. we specialize in thorough fundamental and technical research analysis in equity and commodity market to provide best equity and commodity tips to traders and investors. we provide intraday as well as delivery stock tips in NSE and BSE and commodity tips in MCX and NCDEX. Get our more services:- Intraday stock tips Financial advisory company Share market company Stock Tips * Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. * CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

8. CAPITALSTARSFINANCIALRESEARCHPVT.LTD. BRANCH OFFICE Capitalstars Financial Research Private Limited PLOT NO.32, MECHANIC NAGAR EXTENSION,IDA SCHEME NO.54,VIJAYNAGAR INDORE REGISTERED OFFICE PLOT NO.12, SCHEME NO.78 PART-2, VIJAY NAGAR, INDORE Email:-backoffice@capiltalstars.in Contact us :- 9977499927, 9039012727 Report Is Checked by Investment Advisor: Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.